Indian stocks: Visit www.stage2stocks.com →

NuCana plc

Stage 4 · Declining · week 16

As of Oct 22, 2026, NuCana is in Stage 4, the downtrend phase, now in week 16 (since Jul 2, 2026). It closed at $0.96, 78.3% below its 52-week high and below its 200-day average, which is falling.

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. More about the company

$0.96
-2.17% today
$4.0M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NCNA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 30w
S4 18w
S4 58w
S4 24w
S4 16w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 30w → S1 4w → S4 18w → S1 7w → S4 58w → S1 4w → S4 24w → S1 5w → S4 16w current
Total tracked: 166 weeks across 9 stage runs.

NCNA among Biotechnology459th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…459NCNAStage 4 · wk 1612−26.7%
vs 52W High
-78.3%
$0.96 lo$4.43 hi
78.3% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 16
1w13w26w
Week 16, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-47.4%
200 DMA: $1.82 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.22x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-26.7%
3M
-25.6%
6M
-55.3%
YTD
-73.6%
1Y
-77.2%
Scan Membership
Breakout Watch
Latest: 2023-02-08
4 appearances in last 60 days. First seen: 2021-02-18.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 16 · Vol 0.22x
2026-10-21S4
Wk 16 · Vol 0.21x
2026-10-20S4
Wk 16 · Vol 0.20x
2026-10-19S4
Wk 16 · Vol 0.15x
2026-10-16S4
Wk 15 · Vol 0.32x
2026-10-15S4
Wk 15 · Vol 0.38x
2026-10-14S4
Wk 15 · Vol 0.26x
2026-10-13S4
Wk 15 · Vol 0.36x
2026-10-12S4
Wk 15 · Vol 0.20x
2026-10-09S4
Wk 14 · Vol 0.47x
2026-10-08S4
Wk 14 · Vol 0.24x
2026-10-07S4
Wk 14 · Vol 0.36x
Moving averages & range
50 DMA
$1.30
200 DMA
$1.82
52W High
$4.43
52W Low
$0.96
5D Low
$0.96
Resistance levels (recent highs)
20d High
$1.35
60d High
$1.76
120d High
$2.33
250d High
$4.43
Next resistance
+40.6%
to 20d High
ROE
-70.3%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.2

NuCana: quick answers

What stage is NuCana in?

As of Oct 22, 2026, NuCana (NCNA) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 2, 2026 and is in week 16. What the four stages mean

Is NuCana in an uptrend?

No. NuCana is in a Stage 4 downtrend. It trades 47.4% below its 200-day average, which is falling.

How far is NuCana from its 52-week high?

NuCana closed at $0.96 on Oct 22, 2026, 78.3% below its 52-week high of $4.43. Its 52-week low is $0.96.

How has NuCana performed over the past year?

As of Oct 22, 2026, NuCana is down 77.2% over the past year and down 73.6% so far in 2026.

Which sector and industry is NuCana in?

NuCana is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.